版本:
中国

BRIEF-VBL Therapeutics presents data on immuno-oncology drug

April 4 Vascular Biogenics Ltd-

* VBL Therapeutics presents data on mospd2, a novel immuno-oncology target

* Vascular Biogenics Ltd - study observed from clinical biopsies that mospd2 is prevalent in invasive human breast cancer tissue

* Vascular Biogenics Ltd - study observed from clinical biopsies that levels of mospd2 correlate to breast cancer invasiveness

* Vascular Biogenics - it was further observed that knockdown of mospd2 in human breast cancer cell line using crispr technology led to blockade of egf signaling

* Vascular Biogenics Ltd -mospd2 knockdown using crispr technology led to significant reduction of breast cancer cell migration in vitro, metastasis in mouse model

* Vascular Biogenics Ltd - "believe that mospd2 may be involved in regulation of cell motility in addition to breast cancer" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐